ASND
Ascendis Pharma AS
NASDAQ: ASND · HEALTHCARE · BIOTECHNOLOGY
$220.28
-0.81% today
Updated 2026-04-29
Market cap
$13.61B
P/E ratio
—
P/S ratio
18.90x
EPS (TTM)
$-4.40
Dividend yield
—
52W range
$151 – $251
Volume
0.7M
Ascendis Pharma AS (ASND) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-652000.00 | $6.31M | $-18.40M | $-43.47M | $-60.18M | $-95.10M | $-138.80M | $-175.94M | $-271.55M | $-417.65M | $-495.70M | $-467.36M | $-306.20M | $51.77M |
| Capital expenditures | $291000.00 | $1.20M | $405000.00 | $1.04M | $672000.00 | $941000.00 | $2.65M | $5.16M | $21.55M | $24.23M | $14.49M | $2.44M | $1.43M | $8.15M |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $125000.00 | $671000.00 | $1.27M | $1.71M | $7.32M | $9.71M | $19.65M | $37.49M | $53.17M | $66.83M | $64.18M | $66.66M | $95.51M | $116.17M |
| Free cash flow | $-943000.00 | $5.12M | $-18.81M | $-44.51M | $-60.85M | $-96.04M | $-141.45M | $-181.09M | $-293.10M | $-441.88M | $-510.19M | $-469.80M | $-307.62M | $43.62M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | $33.14M | $5.06M | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |